Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
17 participants
INTERVENTIONAL
2023-03-15
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physiological Effects of Stevia Consumption in Humans
NCT03993418
The Effect of Artificial Sweeteners on Blood Glucose Response
NCT01246492
To Compare the Effects of Non-nutritive Sweeteners Intake in Subjects With T2DM
NCT03680482
Effects of Low Calorie Sweeteners on Dietary Intakes, Hunger, Appetite and Satiety
NCT02297880
Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults
NCT01115088
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In a previous set of studies from our group we showed that a single-dose of a stevia-sweetened beverage prior to lunch leads a lower energy intake compared to consuming water or a sugar-sweetened beverage (Stamataki et al J Nutr. 2020; 150(5):1126-1134. doi: 10.1093/jn/nxaa038). This effect was confirmed to be present in the long-term, as in another 12-weeks trial we demonstrated that individuals in the stevia group (they started consuming stevia drops twice daily with habitual drinks before their meals) demonstrated a significant spontaneous reduction in energy intake compared to the control group (Stamataki et al Nutrients. 2020;12(10):3049. doi: 10.3390/nu12103049).
In a nutshell, this research so far has showed that stevia consumption elicits benefits in appetite and energy intake, without affecting physiological responses such as postprandial glucose response. Taking this research a step further, it is crucial now to answer whether sweetness without calories was the key component of these outcomes, in other words would stevia have the same effects if it was not tasted, if sweet taste (in the oral cavity) was bypassed?
As such the main aim of this study is to evaluate the effects of stevia in a capsule vs placebo on appetite and energy intake and elucidate whether stevia elicits similar effects when sweet taste is bypassed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Participants will attend 2 testing sessions, where they will consume either the stevia capsule or the placebo capsule in a double-blind randomised crossover design.
rebaudioside A
rebaudioside A encapsulated in a vegetarian capsule
Placebo
carboxymethylcellulose encapsulated in a vegetarian capsule
rebaudioside A
Participants will attend 2 testing sessions, where they will consume either the stevia capsule or the placebo capsule in a double-blind randomised crossover design.
rebaudioside A
rebaudioside A encapsulated in a vegetarian capsule
Placebo
carboxymethylcellulose encapsulated in a vegetarian capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rebaudioside A
rebaudioside A encapsulated in a vegetarian capsule
Placebo
carboxymethylcellulose encapsulated in a vegetarian capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18.5-24.9 kg/m2
* DEBQ for restraint eating ≤ 3
* Healthy - general good health
* Currently not taking any medication (other than females taking the oral contraceptives, or medication that does not affect taste, and glucose response)
* Regular breakfast eaters (≥5 times per week)
* Stable weight, ≤ 5 kg last 3 months
* No self-reported food allergy or intolerance to foods supplied during the study
* The participant is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
* The participant is able to read, comprehend and record information written in English.
* A signed and dated written informed consent is obtained from the participant.
Exclusion Criteria
* BMI ≥25 kg/m2 and \<18.5kg/m2
* Subjects who are currently on a diet
* Subjects who follow special diets for weight maintenance, such as Atkins Diet, Weight Watchers, gluten-free diet, The Zone diet, Raw Food Diet etc.
* Vegetarians, vegans
* Subjects having breakfast fewer than 5 times per week.
* Presence of any chronic condition requiring medication that might affect our results (e.g. diabetes, mental diseases, gastrointestinal diseases)
* Subjects with eating disorders (binge eating disorder, bulimia etc)
* Subjects who are currently experiencing anxiety or depression.
* Participants who drink more than the NHS guidelines (14 units per week)
* Participants who are, or may be, pregnant, or currently lactating.
* Subjects who regularly consume dietary supplements for weight loss, muscle building etc.
* Subjects who have aversions to foods related with the study.
* Subjects with food allergies or intolerance related with the foods/ drinks of the study.
* Habitual NNS consumers, \>1 can of diet beverage or \>1 sachet of low calorie sweeteners (corresponding to 1 spoonful) per week.
* The participant cannot read, comprehend and record information written in English.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Manchester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nikoleta Stamataki
Dr Nikoleta Stamataki
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Manchester
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-15284-25905
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.